First, the prognostic impact of FLT3 mutation in AML patients was evaluated using data from the article of Bullinger L et al. The survival analyses suggested that mutant FLT3 was significantly associated with poor overall survival (OS, P<0.001), relapse-free survival (RFS, P<0.01), event-free survival (EFS, P<0.01) in AML patients (Figure 2). This evidence concerns the gene FLT3 and acute myeloid leukemia.